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1. INTRODUCTION {#cam42338-sec-0001}
===============

Translation is the second step in the process of protein biosynthesis, and translation initiation is the first step in the translation process. The eukaryotic initiation factor 3 (EIF3) family plays an important role in eukaryotic translation. Moreover, eukaryotic translation initiation factor 3 subunit A (EIF3a) is the largest subunit of EIF3 family, which is a key player in all steps of translation initiation.[1](#cam42338-bib-0001){ref-type="ref"}

Circular RNAs (circRNAs) are a class of RNAs that have a closed loop structure and distinct from traditional linear RNAs. Up to date, investigating circRNAs functions has become a global hot spot. Previous studies showed that circRNA could function as miRNA sponges and transcriptional regulators. In addition, they can be translated into proteins or interact with RNA‐binding proteins (RBPs).[2](#cam42338-bib-0002){ref-type="ref"}

There have been reports that some genes and the circRNAs transcribed from them have biological functions at the same time. It is reported that DLG associated protein 4 (DLGAP4) is directly linked with brain diseases,[3](#cam42338-bib-0003){ref-type="ref"} such as early‐onset cerebellar ataxia,[4](#cam42338-bib-0004){ref-type="ref"} and circDLGAP4 may serve as a novel clinical treatment target for acute ischemic stroke.[5](#cam42338-bib-0005){ref-type="ref"} Increasing evidence indicates that homeodomain‐interacting protein kinase 3 (HIPK3) is a kinase gene in huntingtin disease,[6](#cam42338-bib-0006){ref-type="ref"}, [7](#cam42338-bib-0007){ref-type="ref"} and a recent study has found that silencing circHIPK3 significantly inhibits human cell growth.[8](#cam42338-bib-0008){ref-type="ref"} In addition, circHIPK3 can mediate the retinal vascular dysfunction in diabetes mellitus.[9](#cam42338-bib-0009){ref-type="ref"} Studies show that the circRNA transcribed from eukaryotic translation initiation factor 3 subunit J (EIF3J) can affect the expression and function of EIF3J.[10](#cam42338-bib-0010){ref-type="ref"} Poly (A) binding protein interacting protein 2 (PAIP2) can limit productive cytomegalovirus replication,[11](#cam42338-bib-0011){ref-type="ref"} and its expression is influenced by the circRNA transcribed from PAIP2.[10](#cam42338-bib-0010){ref-type="ref"}

Considering the regulatory effects of circRNAs on their parental genes with biologically important function, these circRNAs are believed to have some biological functions. Moreover, circRNAs have both functional similarities and differences compared with their parental genes, and can even affect the function of their parental genes. In this case, we speculate that the circRNAs transcripts derived from EIF3a also play an important biological role in humans.

2. MATERIALS AND METHODS {#cam42338-sec-0002}
========================

2.1. Cell culture {#cam42338-sec-0003}
-----------------

The A549 human lung cancer cell line was purchased from the Chinese Academy of Sciences (Shanghai, China) and the A549/DDP human lung cancer drug‐resistant cell line was obtained from the cell biology research laboratory and Modern Analysis Testing Center of Central South University (Changsha, China). All the cell lines were maintained as adherent cell cultures in RPMI 1640 medium (Gibco, Life Technologies, USA) supplemented with 10% fetal bovine serum (FBS, 10099‐141; Gibco, MA, USA). Besides, the A549/DDP cell line was cultured in medium with 2 mg/L cisplatin (Sigma, P4394) to maintain the drug‐resistant phenotype before experimentation. Cells were cultured at 37°C in a humidified atmosphere of 5% CO~2~.

2.2. Drug sensitivity assay {#cam42338-sec-0004}
---------------------------

Cells were seeded in 96‐well plates (4,000 cells/well) and cultured with different concentrations of cisplatin for 48 hours at 37°C in a humidified atmosphere of 5% CO~2~, followed by incubation with CCK‐8 solution. Then the cells' viability was detected by measuring the absorbance at 450 nm using an Eon plate reader. The half‐maximal inhibitory concentration (IC~50~) was calculated from the relative survival curves.

2.3. RNA extraction, RNA RNase R treatment, and real‐time quantitative RT‐PCR {#cam42338-sec-0005}
-----------------------------------------------------------------------------

Total RNA was extracted using TRIzol (Invitrogen, CA, USA) according to the instructions. Cytoplasmic and nuclear RNAs were extracted using Cytoplasmic and Nuclear RNA Purification Kit (Norgen, Canada) according to the manufacturer\'s instructions. RNA RNase R treatment was carried out for 10 minutes at 37°C using 1ul RNase R (20 U/UL). Primescript RT Reagent Kit with gDNA Eraser (Takara Bio Inc, Japan) was used for synthesizing cDNA according to the manufacturer\'s instructions. CircRNAs expression was assessed by real‐time quantitative RT‐PCR using SYBR Premix Dimer Eraser assay kits. Real‐time quantitative RT‐PCR was performed through the Roche LightCycler 480 PCR System.

2.4. RNA immunoprecipitation assay {#cam42338-sec-0006}
----------------------------------

RNA immunoprecipitation assay (RIP) was performed using EZMagna RIP Kit (Millipore, Billerica, MA) according to the manufacturer\'s instructions. A549 cell lysates were incubated with anti‐rabbit AGO~2~antibodies (Abcam, Cambridge, MA) or anti‐rabbit IgG antibodies (Millipore, Billerica, MA).

2.5. Western blot analysis {#cam42338-sec-0007}
--------------------------

After transfection for 48 hours, western blot assay was carried out using the standard method, and then transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA). After 2 hours of blocking, PVDF membranes were incubated with anti‐mouse β‐actin antibodies (Sigma‐Aldrich) and anti‐rabbit EIF3a antibodies (Cell Signaling Technology, USA) overnight at 4°C.

2.6. Differentially expressed gene analysis and survival analysis {#cam42338-sec-0008}
-----------------------------------------------------------------

We used THE HUMAN PROTEIN ATLAS (THPA) (<https://www.proteinatlas.org/>), THE CANCER GENOME ATLAS (TCGA) (<https://cancergenome.nih.gov/>) and ONCOMINE (<https://www.oncomine.org>) Database to identify the differential expression of EIF3a in various tissues and tumors. The prognostic value of EIF3a level in lung cancer and ovarian cancer are from KAPLAN‐MEIER PLOTTER (KMP) (<http://kmplot.com/analysis/>) Database.

2.7. Prediction for circEIF3as, circEIF3as‐RBPs axis and coding potential {#cam42338-sec-0009}
-------------------------------------------------------------------------

CircEIF3as were predicted using CIRCBASE (<http://circbase.org/>) Database. The target RBPs of circEIF3as were predicted based on circRNA Interactome (<https://circinteractome.nia.nih.gov/>), RBPDB (<http://rbpdb.ccbr.utoronto.ca/>), catRAPID (<http://service.tartaglialab.com/page/catrapid_group>) and Cancer‐Specific CircRNA (<http://gb.whu.edu.cn/CSCD/>) Database. The graph of the circEIF3as‐RBPs axis was drawn with the Cytoscape 3_6\_0. The Internal Ribosome Entry Site (IRES) and Open Reading Frame (ORF) of circEIF3as were predicted based on Circbank (<http://www.circbank.cn/index.html>) and ORF finder (<https://www.ncbi.nlm.nih.gov/orffinder/>) Database.

2.8. Functional enrichment analysis {#cam42338-sec-0010}
-----------------------------------

During functional enrichment analysis of circEIF3as, the online analysis tool‐Metascape (<http://metascape.org/gp/index.html#/main/step1>) was utilized to perform gene ontology (GO) enrichment analysis.

2.9. Statistical analysis {#cam42338-sec-0011}
-------------------------

The SPSS 19.0 software was used for general statistical analysis. Survival rate was calculated using the Kaplan‐Meier method.

2.10. Data availability statement {#cam42338-sec-0012}
---------------------------------

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

3. RESULTS {#cam42338-sec-0013}
==========

3.1. The expression of EIF3a in tissues and tumors {#cam42338-sec-0014}
--------------------------------------------------

In previous studies, EIF3a was thought to be associated with the occurrence, metastasis, prognosis and treatment of cancer. It has been reported that EIF3a has biological function in lung cancer,[12](#cam42338-bib-0012){ref-type="ref"} breast cancer,[13](#cam42338-bib-0013){ref-type="ref"} pancreas cancer,[14](#cam42338-bib-0014){ref-type="ref"} gastric cancer,[15](#cam42338-bib-0015){ref-type="ref"} oral cavity cancer,[16](#cam42338-bib-0016){ref-type="ref"} colon cancer,[17](#cam42338-bib-0017){ref-type="ref"} esophagus cancer,[18](#cam42338-bib-0018){ref-type="ref"} ovary cancer,[19](#cam42338-bib-0019){ref-type="ref"} urinary bladder cancer,[20](#cam42338-bib-0020){ref-type="ref"} cervix cancer.[21](#cam42338-bib-0021){ref-type="ref"} Besides these, EIF3a is also emerging as a new potential anticancer drug therapeutic target in clinic, which improves the cisplatin sensitivity in lung cancer [22](#cam42338-bib-0022){ref-type="ref"}, [23](#cam42338-bib-0023){ref-type="ref"}, [24](#cam42338-bib-0024){ref-type="ref"} and ovarian cancer.[19](#cam42338-bib-0019){ref-type="ref"} We use THPA Database to compare the expression level of EIF3a in different tissues (Figure [1](#cam42338-fig-0001){ref-type="fig"}A), where EIF3a tissue data are reported as a mean transcript per million experiment samples. The color‐coding is based on tissue groups, which consists of tissues with common functional features. The expression level of EIF3a in 17 cancer types is generated by the TCGA Database, in which the cancer types are color‐coded according to the type of normal organ that the cancer originates from (Figure [1](#cam42338-fig-0001){ref-type="fig"}B). The differential expression of EIF3a in various types of tumors is illustrated in the data from ONCOMINE Database (Figure [1](#cam42338-fig-0001){ref-type="fig"}C), where the red/blue color indicates high/low expression, respectively, and the darker color means higher/lower level of expression.

![Panel A, EIF3a in different tissues, the data are obtained from THE HUMAN PROTEIN ATLAS (THPA) Database. Panel B, EIF3a in different cancers, the data are obtained from THE CANCER GENOME ATLAS (TCGA) Database. Panel C, The expression of EIF3a in various tumors, the data comes from ONCOMINE Database. EIF3a, eukaryotic translation initiation factor 3 subunit A](CAM4-8-4159-g001){#cam42338-fig-0001}

3.2. Association of prognostic value with EIF3a expression level {#cam42338-sec-0015}
----------------------------------------------------------------

As shown in Figure [1](#cam42338-fig-0001){ref-type="fig"}, EIF3a is highly expressed in various tissues and cancers, and on the other hand, EIF3a could present as both biomarkers and potential anticancer drug target in lung cancer and ovarian cancer.[19](#cam42338-bib-0019){ref-type="ref"}, [22](#cam42338-bib-0022){ref-type="ref"}, [23](#cam42338-bib-0023){ref-type="ref"}, [24](#cam42338-bib-0024){ref-type="ref"} Therefore, lung cancer and ovarian cancer will be taken as an example to analyze the impact of EIF3a on the survival of patients who suffered from these cancers. The results suggest that EIF3a has a significant effect on the survival rate of patients with lung cancer, but has little effect on the prognosis of patients with ovarian cancer (Figure [2](#cam42338-fig-0002){ref-type="fig"}A,B). The results are collected from KMP Database.

![Panel A, The prognostic value of EIF3a level in lung cancer patients. Panel B, The prognostic value of EIF3a level in ovarian cancer patients. Panel C, Thirty‐one circRNAs derived from EIF3a. Panel D, The type and quantity of circEIF3as. EIF3a, eukaryotic translation initiation factor 3 subunit A. circRNA, circular RNA](CAM4-8-4159-g002){#cam42338-fig-0002}

3.3. The circRNAs screening from EIF3a {#cam42338-sec-0016}
--------------------------------------

Eukaryotic translation initiation factor 3 subunit A is a highly conserved gene located at 10q26.11 with 22 exons, spanning a 46‐kb DNA region.[25](#cam42338-bib-0025){ref-type="ref"} Human EIF3a is a 170‐kDa protein consisting of 1382 amino acids. According to the record in the CIRCBASE Database, a total of 31 circRNAs are derived from EIF3a, including 8 exon‐originated circular RNAs and 23 exons‐introns‐originated circular RNAs (Figure [2](#cam42338-fig-0002){ref-type="fig"}C,D, Table [1](#cam42338-tbl-0001){ref-type="table"}).

###### 

Summary of circRNAs screening from EIF3a

  　   Circular RNA ID    Location                    Genomic length   Spliced length   Type
  ---- ------------------ --------------------------- ---------------- ---------------- -----------
  1    hsa_circ_0004350   chr10:120832401‐120833449   1048             492              EIcircRNA
  2    hsa_circ_0004792   chr10:120797749‐120797951   202              202              EcircRNA
  3    hsa_circ_0020136   chr10:120794540‐120830597   36057            4618             EIcircRNA
  4    hsa_circ_0020137   chr10:120796630‐120820356   23726            2692             EIcircRNA
  5    hsa_circ_0020138   chr10:120797749‐120820356   22607            2501             EIcircRNA
  6    hsa_circ_0020139   chr10:120809312‐120818909   9597             1215             EIcircRNA
  7    hsa_circ_0020140   chr10:120810710‐120832565   21855            1942             EIcircRNA
  8    hsa_circ_0020141   chr10:120810710‐120833449   22739            2270             EIcircRNA
  9    hsa_circ_0020142   chr10:120818723‐120820840   2117             507              EIcircRNA
  10   hsa_circ_0020143   chr10:120819113‐120819230   117              117              EcircRNA
  11   hsa_circ_0020144   chr10:120819113‐120840334   21221            1589             EIcircRNA
  12   hsa_circ_0020145   chr10:120820257‐120820356   99               99               EcircRNA
  13   hsa_circ_0020146   chr10:120820257‐120820840   583              204              EIcircRNA
  14   hsa_circ_0020147   chr10:120820257‐120833089   12832            1086             EIcircRNA
  15   hsa_circ_0020148   chr10:120824910‐120825082   172              172              EcircRNA
  16   hsa_circ_0020149   chr10:120824910‐120833089   8179             882              EIcircRNA
  17   hsa_circ_0020150   chr10:120824910‐120833449   8539             1073             EIcircRNA
  18   hsa_circ_0020151   chr10:120828957‐120830597   1640             409              EIcircRNA
  19   hsa_circ_0020152   chr10:120832401‐120832565   164              164              EcircRNA
  20   hsa_circ_0020153   chr10:120832401‐120833089   688              301              EIcircRNA
  21   hsa_circ_0092856   chr10:120801769‐120802132   363              363              EcircRNA
  22   hsa_circ_0092857   chr10:120809312‐120810833   1521             462              EIcircRNA
  23   hsa_circ_0092858   chr10:120810710‐120816365   5655             237              EIcircRNA
  24   hsa_circ_0092859   chr10:120810710‐120818909   8199             876              EIcircRNA
  25   hsa_circ_0092860   chr10:120816251‐120816365   114              114              EcircRNA
  26   hsa_circ_0092861   chr10:120816447‐120816552   105              105              EcircRNA
  27   hsa_circ_0092862   chr10:120818723‐120830597   11874            1088             EIcircRNA
  28   hsa_circ_0092863   chr10:120828957‐120833449   4492             901              EIcircRNA
  29   hsa_circ_0092864   chr10:120830397‐120832565   2168             364              EIcircRNA
  30   hsa_circ_0092865   chr10:120832542‐120833089   547              160              EIcircRNA
  31   hsa_circ_0092866   chr10:120832952‐120833449   497              328              EIcircRNA

Abbreviation: EIF3a, eukaryotic translation initiation factor 3 subunit A.
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3.4. Validation for the differential expression level and drug sensitivity of circEIF3as {#cam42338-sec-0017}
----------------------------------------------------------------------------------------

The circEIF3as is verified by real‐time quantitative reverse transcription‐PCR (qRT‐PCR) in A549 and A549/DDP cell line. We designed two pairs of primers to each circEIF3a for qRT‐PCR (Table [S1](#cam42338-sup-0001){ref-type="supplementary-material"}). The results show that only two circRNAs transcribed from EIF3a (hsa_circ_0004350, hsa_circ_0092857) have differential expression in the two cell lines, and the rest are without differential expression or even with no expression in the two cell lines (Figure [3](#cam42338-fig-0003){ref-type="fig"}A). The locus of hsa_circ_0004350 is on chromosome 10:120.832.401‐120.833.449 in humans, while hsa_circ_0092857 is located on chromosome 10:120.809.312‐120.810.833 in humans. Both two circRNAs contain three exons and two introns (Figure [3](#cam42338-fig-0003){ref-type="fig"}B,C). The data were obtained from UNIVERSITY OF CALIFORNIA SANTA CRUZ GENOME BROWSER Database. Next, we explored whether hsa_circ_0004350 and hsa_circ_0092857 could affect cisplatin resistance in lung cancer cells, we found that down‐regulating the expression of hsa_circ_0004350 and hsa_circ_0092857 could affect cisplatin resistance in lung cancer cells (Figure [3](#cam42338-fig-0003){ref-type="fig"}D).

![Panel A, The expression of hsa_circ_0004350 and hsa_circ_0092857 in A549 and A549/DDP cell line. (\**P* \< 0.05; \*\**P* \< 0.01). The diagram of position: hsa_circ_0004350 (panel B) and hsa_circ_0092857 (panel C). Panel D, The half‐maximal inhibitory concentration of hsa_circ_0004350 and hsa_circ_0092857](CAM4-8-4159-g003){#cam42338-fig-0003}

3.5. Possible biological functions of circEIF3as {#cam42338-sec-0018}
------------------------------------------------

Circular RNAs have different biological functions by acting as miRNA sponges or transcriptional regulators, and some of them are reported to have translation potential and can interact with RBPs. We conducted a series of experiments to determine the possible biological functions of circEIF3as. Compared with EIF3a mRNA, circEIF3as were resistant to RNase R digestion (Figure [4](#cam42338-fig-0004){ref-type="fig"}A). Subcellular fractionation assay indicated the cytoplasmic and nuclear enrichment and localization of circEIF3as (Figure [4](#cam42338-fig-0004){ref-type="fig"}B). RIP for AGO~2~ in A549 cells was performed, the results showed that circEIF3as were not accumulated in the AGO~2~pellet (Figure [4](#cam42338-fig-0004){ref-type="fig"}C). In addition, we performed qRT‐PCR and western blot assays to investigate whether the circEIF3as can affect the expression of EIF3a (Figure [4](#cam42338-fig-0004){ref-type="fig"}D,E). In order to explore the translation potential of circEIF3as, we predicted the IRES and ORF via Circbank and ORF finder Database. Hsa_circ_0004350 has one IRES but no ORF, hsa_circ_0092857 has no IRES and ORF (Figure [4](#cam42338-fig-0004){ref-type="fig"}F). These data indicated that two potential circEIF3as were predominantly localized in the nucleus and were not accumulated in the AGO~2~ pellet. Furthermore, they had little effect on the expression of EIF3a and relatively low protein‐encoding potential. Taken together, we speculate that the two circEIF3as are involved in RBPs‐mediated biological processes.

![Panel A, After RNase R treatment, the expression levels of EIF3a and circEIF3as were determined by qRT‐PCR. Panel B, Subcellular fractionation assay was used to detect the localization of hsa_circ_0004350 and hsa_circ_0092857. Panel C, RIP assay indicating that hsa_circ_0004350 and hsa_circ_0092857 were not substantially accumulated in the AGO~2~ pellet. Hsa_circ_0004350 and hsa_circ_0092857 has little effect on the expression of EIF3a according to qRT‐PCR (panel D) and western blot (panel E) assays. Panel F, Protein‐encoding potential of circEIF3as. EIF3a, eukaryotic translation initiation factor 3 subunit A. EIF3a, eukaryotic translation initiation factor 3 subunit A; qRT‐PCR, quantitative reverse transcription‐PCR; RIP, RNA immunoprecipitation assay](CAM4-8-4159-g004){#cam42338-fig-0004}

3.6. Construction of the circEIF3as/RBPs axis regulation network {#cam42338-sec-0019}
----------------------------------------------------------------

To explore the function of two potential circEIF3as, we predicted the circEIF3as/RBPs axis via circRNA Interactome, RBPDB, catRAPID, and Cancer‐Specific CircRNA Database. We used the four databases to determine the target RBPs for each circEIF3a and combined the RBPs of four databases as the target for each circEIF3a (Table [S2](#cam42338-sup-0002){ref-type="supplementary-material"}). The network of circEIF3as/RBPs axis is illustrated using Cytoscape (Figure [5](#cam42338-fig-0005){ref-type="fig"}A).

![Panel A, The network of circEIF3as/RBPs axis. GO enrichment analysis of hsa_circ_0004350 (panel B) and hsa_circ_0092857 (panel C). Panel D, GO analysis on RBPs regulated by two circEIF3as. GO, gene ontology; RBPs, RNA‐binding proteins](CAM4-8-4159-g005){#cam42338-fig-0005}

3.7. Functional enrichment analysis of circEIF3as/RBPs {#cam42338-sec-0020}
------------------------------------------------------

To identify the biological roles of hsa_circ_0004350 and hsa_circ_0092857, we annotated their functions by the GO enrichment analysis. We used Metascape to predict the biological functions of hsa_circ_0004350 (Figure [5](#cam42338-fig-0005){ref-type="fig"}B) and hsa_circ_0092857 (Figure [5](#cam42338-fig-0005){ref-type="fig"}C). It is interesting to note that hsa_circ_0004350 and hsa_circ_0092857 are significantly associated with translation regulation. Next, we performed GO analysis on the overlapping RBPs regulated by two circEIF3as, we found that these overlapping RBPs were also regulators of translation (Figure [5](#cam42338-fig-0005){ref-type="fig"}D). These results suggest that the two circEIF3as may have a function synergy effect with the parental EIF3a gene.

4. DISCUSSION {#cam42338-sec-0021}
=============

In the past few years, with the development of high‐throughput sequencing and bioinformatics analysis, circRNAs have gradually become a research topic, which were once considered as transcriptional noise. CircRNAs have also been recognized as transcriptional regulators and miRNAs sponges. In addition, they can interact with RBPs and some of them can even be translated into proteins.

As the largest subunit of EIF3, EIF3a plays a bridging role in the initiation of translation. Numbers of studies have shown that EIF3a is involved in the initiation of mRNA translation in yeast cells and mammalian cells,[26](#cam42338-bib-0026){ref-type="ref"} and also regulates the initiation of protein translation. In the meantime, EIF3a is involved in the regulation of cell cycle,[27](#cam42338-bib-0027){ref-type="ref"} and shows a significant correlation with cell growth [28](#cam42338-bib-0028){ref-type="ref"} and differentiation.[29](#cam42338-bib-0029){ref-type="ref"} Recent studies have found that EIF3a is closely related to the occurrence, development, prognosis and chemotherapy efficacy of tumors.[17](#cam42338-bib-0017){ref-type="ref"} Moreover, EIF3a gene polymorphism is also associated with the susceptibility of malignant tumors.[30](#cam42338-bib-0030){ref-type="ref"}

The above results indicate that EIF3a exerts a crucial influence on the physical fitness of human beings. EIF3a can be transcribed into both mRNA and circRNAs. Until now, there is no report about circRNAs transcribed from EIF3a. Therefore, we bravely assumed that circEIF3as has the biological function. We detected the expression of circEIF3as in the lung cancer cell line and lung cancer drug‐resistant cell line of human, the results showed that hsa_circ_0004350 and hsa_circ_0092857 had differential expression in two cell lines. Moreover, we found that down‐regulating the expression of hsa_circ_0004350 and hsa_circ_0092857 could affect cisplatin resistance in lung cancer cells. By using bioinformatical methods, we predicted the RBPs of these two circEIF3as in four databases. Next, we performed GO enrichment analysis of hsa_circ_0004350 and hsa_circ_0092857 to annotate the biological functions, we found that the two circEIF3as were related to translation regulation, showing that they may have a function synergy effect with EIF3a.

In conclusion, we systematically analyzed the expression of EIF3a in various tissues and tumors, and also discussed the prognostic value of EIF3a in lung cancer patients and ovarian cancer patients. Our study for the first time revealed the expression signatures of the circRNAs transcripts derived from EIF3a in lung cancer. Furthermore, we established the biological functions of circEIF3as with different bioinformatical analyses. The further studies on functions and mechanisms underlying hsa_circ_0004350 and hsa_circ_0092857 are being carried out in our laboratory. Our findings support that hsa_circ_0004350 and hsa_circ_0092857 are derived from the translation initiation factor‐EIF3a, moreover, they are involved in drug sensitivity and translational regulation. These results suggest that these two circEIF3as may have functional synergy with their parental gene‐EIF3a, and may also serve as potential targets for lung cancer treatment like EIF3a. These data provide the basis for further studies on the diagnosis, treatment and biological function of circEIF3as in lung cancer.
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